Brain Cancer Clinical Trials in Austin

Showing 81-100 of 143 trials

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406

Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by the administration of intravenous pembrolizumab (an immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease progression. Funding Source-FDA OOPD

Brain CancerBrain NeoplasmGlioma+8 more

DNAtrix, Inc.49 participantsStarted Oct 2016

Little Rock, Arkansas, United States • Los Angeles, California, United States • Chicago, Illinois, United States +12 more locations

TERMINATEDPhase 362 miles

UNITE Study: Understanding New Interventions With GBM ThErapy

NCT03419403

The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).

Glioblastoma Multiforme

AbbVie40 participantsStarted Jul 2018

Los Angeles, California, United States • Tampa, Florida, United States • Chicago, Illinois, United States +19 more locations

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

UNITE Study: Understanding New Interventions With GBM ThErapy

Brain Cancer Trials in Other Cities

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

ANG1005 in Patients With Recurrent High-Grade Glioma

Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer

Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Gliogene: Brain Tumor Linkage Study

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

A Study in Subjects With Recurrent Malignant Glioma

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

Other Conditions in Austin